Burris J F, Goldstein J, Zager P G, Sutton J M, Sirgo M A, Plachetka J R
J Clin Hypertens. 1986 Sep;2(3):285-93.
The side-effect profile of labetalol was assessed in 34 patients with mild to moderate essential hypertension who had previously experienced side effects during beta-blocker therapy. The most frequently reported beta-blocker side effects were fatigue, impotence, cold extremities, and depression. After discontinuing their previous beta-blocker for 4 weeks, labetalol was titrated (100-400 mg b.i.d.) to achieve blood pressure control. Twenty-seven of 34 patients did not have a recurrence of a beta-blocker related side effect while receiving labetalol. The most common new side effect with labetalol was dizziness (3 patients). As judged by the attending physician and the patient, labetalol was better tolerated than conventional beta-blocker therapy in 30 of 34 patients (88%). Twenty-four of 34 patients (71%) preferred labetalol over previous therapy. Labetalol controlled blood pressure in 30 of 34 patients (88%). At equal antihypertensive doses, some side effects common to beta-blockers are seen less frequently with labetalol.
对34例轻度至中度原发性高血压患者进行了拉贝洛尔副作用情况的评估，这些患者之前在β受体阻滞剂治疗期间出现过副作用。最常报告的β受体阻滞剂副作用为疲劳、阳痿、四肢发冷和抑郁。在停用之前的β受体阻滞剂4周后，对拉贝洛尔进行滴定（每日两次，每次100 - 400毫克）以实现血压控制。34例患者中有27例在接受拉贝洛尔治疗时未出现与β受体阻滞剂相关的副作用复发。拉贝洛尔最常见的新副作用是头晕（3例患者）。根据主治医生和患者的判断，34例患者中有30例（88%）对拉贝洛尔的耐受性优于传统β受体阻滞剂治疗。34例患者中有24例（71%）更喜欢拉贝洛尔而非之前的治疗。34例患者中有30例（88%）使用拉贝洛尔后血压得到控制。在同等降压剂量下，拉贝洛尔出现一些β受体阻滞剂常见副作用的频率较低。
